Abstract
The JenaValve (JV) transcatheter aortic valve implantation (TAVI) device is the first so-called third-generation device, as it incorporates many new features, such as treatment for aortic stenosis and aortic regurgitation, as well as anatomic positioning and easy deployment precisely within the aortic annulus. Its transfemoral model is expected to launch on the European market in 2018. The development started as early as 1995, and did not find support at that time from physicians, industry, or scientific grants. The first transapical model was launched on the market in 2011 for the treatment of aortic stenosis, and the only TAVI device for the treatment of aortic regurgitation came onto the market in 2013.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferrari M, Figulla HR, Schlosser M, et al. Transarterial aortic valve replacement with a self-expanding stent in pigs. Heart. 2004;90:1326–31.
Lauten A, Ferrari M, Petri A, et al. Experimental evaluation of the JenaClip transcatheter aortic valve. Catheter Cardiovasc Interv. 2009;74:514–9.
Seiffert M, Diemert P, Koschyk D, et al. Transapical implantation of a second-generation transcatheter heart valve in patients with noncalcified aortic regurgitation. JACC Cardiovasc Interv. 2013;6:590–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Figulla, H.R., Ferrari, M., Carr-Brendel, V., Lauten, A. (2019). The JenaValve Program for Transcatheter Aortic Valve Implantation. In: Giordano, A., Biondi-Zoccai, G., Frati, G. (eds) Transcatheter Aortic Valve Implantation. Springer, Cham. https://doi.org/10.1007/978-3-030-05912-5_23
Download citation
DOI: https://doi.org/10.1007/978-3-030-05912-5_23
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-05911-8
Online ISBN: 978-3-030-05912-5
eBook Packages: MedicineMedicine (R0)